Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Cellular Pharmacology of F-TAF in Dried Blood Spots

Next Previous
X
Search
Trial Profile

The Cellular Pharmacology of F-TAF in Dried Blood Spots

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir alafenamide (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms TAF-DBS Study

    • Most Recent Events

    • 22 Feb 2023 Results(n=13) assessing cell pharmacology and platelet effects of abacavir/lamivudine and tenofovir alafenamide/emtricitabine in persons with HIV (NCT04301661) and compare them with historical data in persons without HIV (NCT02962739) presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
    • 02 Sep 2021 Results of two studies (DOT-DBS and TAF-DBS) assessing to mimic low, medium, and high adherence, published in the AIDS.
    • 10 Mar 2021 Results (n=36) assessing urine tenofovir levels among individuals taking tenofovir alafenamide at variable dosing intervals, and compare them to a prior study of directly observed therapy tenofovir disoproxil fumarate, presented at the 28th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top